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Aims Intraventricular conduction defects (IVCDs) can impair prognosis of heart failure (HF), but their specific impact is not
well established. This study aimed to analyse the clinical profile and outcomes of HF patients with LBBB, right bundle
branch block (RBBB), left anterior fascicular block (LAFB), and no IVCDs.
Methods
and results
Clinical variables and outcomes after a median follow-up of 21monthswere analysed in 1762 patients with chronic HF and
LBBB (n ¼ 532), RBBB (n ¼ 134), LAFB (n ¼ 154), and no IVCDs (n ¼ 942). LBBB was associated with more marked LV
dilation, depressed LVEF, and mitral valve regurgitation. Patients with RBBB presented overt signs of congestive HF and
depressed right ventricular motion. The LAFB group presented intermediate clinical characteristics, and patients with
no IVCDs were more often women with less enlarged left ventricles and less depressed LVEF. Death occurred in 332
patients (interannual mortality¼ 10.8%): cardiovascular in 257, extravascular in 61, and of unknown origin in 14 patients.
Cardiac death occurred in 230 (pump failure in 171 and sudden death in 59). An adjustedCoxmodel showed higher risk of
cardiac death and pump failure death in the LBBB and RBBB than in the LAFB and the no IVCD groups.
Conclusion LBBB and RBBB are associated with different clinical profiles and both are independent predictors of increased risk of
cardiac death in patients with HF. A more favourable prognosis was observed in patients with LAFB and in those free
of IVCDs. Further research in HF patients with RBBB is warranted.
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Introduction
Intraventricular conduction defects (IVCDs) can probably impair
the clinical course and outcomes of patients with chronic heart
failure (HF) since delayed activation of either the right or left
ventricle shortens the duration of the ventricular diastolic
filling period, and this in turn reduces the stroke volume
and cardiac output.1,2 Moreover, the systolic and diastolic
ventricular asynchrony originating due to the abnormal cardiac
activation sequence3,4 will worsen the already depressed
cardiac output and favour further ventricular volume
remodelling.5,6
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Clinical registries that have analysed the prognostic implications of
bundle branch block in patients with HF7–12 reported different
results. Whereas the presence of LBBB emerges as an independent
prognostic marker in some studies,7,9,10 others found a higher
mortality linked to the presence of right bundle branch block
(RBBB).11,12 Differences in the length of the follow-up period (from
1 up to 5 years)7,10 may account to some extent for the reported
prognostic differences, although the categorization of patients and
the analysis of the causes of death would certainly play an important
role. Indeed, vital status or all-cause mortality instead of a more
precise assessment of different causes of cardiac death are presently
determined inmost studies.On the other hand, the clinical character-
istics associated with different IVCDs cannot be well established
because echocardiographic data are not reported in all studies and,
moreover, they lack information on relevant features such as LV
and left atrial size, or mitral valve assessment.7,10,12,13
This study was therefore undertaken to determine the clinical
characteristics and 21-month follow-up outcomes of chronic HF
in relation to the presence of LBBB, RBBB, and LAFB, and the
absence of IVCDs.
Methods
Study population
We screened 2254 patients with chronic HF entered in the Spanish
Network for the Study of Heart Failure (REDINSCOR).14 Patients
were consecutively recruited between January 2007 and January
2011 at HF units in 18 hospitals. Inclusion criteria were: (i) age older
than 18 years; and (ii) prior hospital admission (.24 h) due to HF
and at least one echocardiographic abnormality (LVEF ≤ 40%, LV end-
diastolic diameter ≥ 60 mm, altered LV relaxation indicating diastolic
dysfunction, or thickness of interventricular septum/LV posterior
wall ≥ 14 mm). All patients were symptomatic (functional NYHA
class II– IV) and were treated according to the established clinical
guidelines. Exclusion criteria were: (i) reversible acute HF; (ii) severe
valvular disease amenable to surgical repair; (iii) right HF secondary
to chronic cor pulmonale; and (iv) concomitant terminal disease.
The investigation conforms with the principles outlined in the Declar-
ation of Helsinki. The protocol was approved by the ethics committees
of all centres, and all patients gave written informed consent to
participate in the study.
Study variables
Data were collected using specifically designed web forms, and quality
control was carried out every month. We recorded 93 clinical vari-
ables at study inclusion, and standard criteria were used to define
them. Cardiovascular risk factors were eventually coded as dichotom-
ous variables (yes/no). Central obesity was defined as abdominal
circumference ≥88 cm in women and ≥ 102 cm in men.15 Body
mass index (kg/m2) was entered as a continuous variable. Anaemia
was defined as haemoglobin ,120 g/L for women and ,130 g/L for
men.16 The plasma levels of NT-proBNP and BNP were dichotomized
for a cut-off value of .118.2 pmol/L and .43.41 pmol/L, respectively.17
The LV mass was determined according to previously published
methods.18 The LV relaxation parameters were calculated according
to transmitral flow patterns.19 Right ventricular (RV) function was esti-
mated by tricuspid annular plane systolic excursion (TAPSE).20 The
estimated glomerular filtration rate (GFR) was calculated using the
MDRD (Modification of Diet in Renal Disease) method.21 Plasma
levels of cardiac troponin I or T were considered ‘high’ according to
the reference cut-off value for each hospital.
Left bundle branch block was defined by a prolonged QRS duration
of ≥ 0.12 s associated with a broad, notched R wave without q waves
in leads I, aVL, and V6, and an rS pattern in lead V1. RBBB was char-
acterized by prolonged QRS duration of ≥ 0.12 s associated with an
R, rSR’, or qR wave in lead V1; wide, slurred S waves in leads I, aVL,
V5, and V6; and a wide terminal r wave in aVR. LAFB was defined
by leftward axis deviation of –458 or more associated with qR wave
in leads I and aVL and an rS pattern in leads II, III, and aVF.
Follow-up
Follow-up data were obtained from the outpatient annual visits or
from the readmission and event reports. Total mortality included all
cardiac and non-cardiac deaths. Cardiac mortality included death due
to pump failure and sudden death. Pump failure death included patients
dying because of refractory HF and patients undergoing urgent cardiac
transplantation. Sudden death was defined as an unexpected natural
death with no apparent cause occurring , 1 h after the onset of
symptoms. Patients lost to follow-up and those submitted to non-
emergency heart transplant were censured for the analysis. The
reported deaths were reviewed by an ad hoc committee.
Statistical analysis
Continuous variables were expressed as the mean+ standard devi-
ation (SD) and the categorical variables are presented as frequency
and percentage. Differences in the categorical variables were assessed
by the x2 test or Fisher’s exact test, and differences in continuous vari-
ables were analysed by analysis of variance (ANOVA). A multivariate
analysis (Cox model) was built to assess the influence of the different
IVCDs on survival, and a Cox proportional hazard regression model
was used to identify independent predictors of readmissions and
cardiac death for each IVCD. Variables showing a significant level in
the univariate model (P, 0.1) were thereafter included in the multi-
variate Cox model following a backward stepwise approach. The
final model was adjusted for those variables categorized as clinically
relevant. Moreover, confounding variables were included when they
carry a change of the effect on the hazard ratio . 10%.22 The propor-
tionality assumption of the models was verified using time-dependent
variables. Variables with .10% of missing data were not included in
the Cox models, and a multivariate regression imputation was
applied, whenever necessary.23 A two-sided P, 0.05 was considered
statistically significant. All analyses were performed using SPSS
(v 19.0) software.
Results
Clinical characteristics
Among the 2254 patients screened, 532 (23.6%) presented LBBB,
134 (6%) RBBB, 154 (6.8%) LAFB, and 942 (41.8%) no IVCDs at in-
clusion. The remaining 492 patients (21.8%) presented left posterior
fascicular block (n ¼ 14), combinedBBB (n ¼ 87), non-specific intra-
ventricular conduction (n ¼ 131), and ventricular pacing rhythm
(n ¼ 260), and they were not included in the analysis. Thus, the
final study population consisted of 1762 patients (mean age 66
years, 68% men, 57% in NYHA class III– IV, mean LVEF of 36%).
As shown in Table 1, there were significant clinical differences
between the study groups. Patients with LBBB had a more frequent
history of dilated cardiomyopathy and presented with the most
J. Cinca et al.878
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline clinical characteristics of 1762 patients with and without intraventricular conduction defects
Variables LBBB
(n 5 532, 30.2%)
RBBB
(n 5 134, 7.6%)
LAFB
(n5 154, 8.7%)
No IVCDs
(n 5 942, 53.5%)
P-value
Age, years 66.8+ 11.6 67.6+ 12.6 68.5+ 13.8 64.7+ 13.7 ,0.001
Sex, male 380 (71%) 101 (75%) 108 (70%) 610 (65%) 0.011
Diabetes mellitus 209 (39%) 58 (43%) 53 (34%) 406 (43%) 0.146
Hypertension 351 (66%) 98 (73%) 111 (72%) 639 (68%) 0.282
Prior AMI 176 (33%) 59 (44%) 45 (29%) 352 (37%) 0.023
Ischaemic heart disease 228 (43%) 70 (52%) 61 (40%) 450 (48%) 0.047
Dilated myocardiopathy 210 (39%) 21 (16%) 49 (32%) 215 (23%) ,0.0001
BMI, kg/m2 28.3+ 4.6 29.3+ 5.8 28.7+ 4.2 29.2+ 5.4 0.011
Central obesity 299 (56%) 91 (68%) 87 (56%) 586 (62%) 0.025
NYHA class, III– IV 316 (59%) 75 (56%) 98 (64%) 512 (54%) 0.081
Orthopnoea 222 (42%) 64 (48%) 76 (49%) 348 (37%) 0.004
Nocturnal dyspnoea 102 (19%) 38 (28%) 36 (23%) 176 (19%) 0.042
Third heart sound 95 (18%) 23 (17%) 14 (9%) 104 (11%) ,0.001
Lower limb oedema 137 (26%) 58 (43%) 54 (35%) 270 (29%) ,0.001
Jugular ingurgitation 129 (24%) 37 (28%) 43 (28%) 168 (18%) ,0.001
Hepatomegaly 76 (14%) 32 (24%) 17 (11%) 108 (11%) ,0.001
Hepatojugular reflex 91 (17%) 27 (20%) 33 (21%) 124 (13%) 0.011
Ascites 27 (5%) 16 (12%) 9 (6%) 48 (5%) 0.013
RR interval, ms 826+ 168 801+ 169 817+ 162 808+ 175 0.223
QRS duration, ms 148+ 28 135+ 28 111+ 25 98+ 20 ,0.0001
AF/flutter 125 (23%) 44 (33%) 37 (24%) 260 (28%) 0.098
LVEDD, mm 65+ 10 57+ 10 61+ 11 58+ 10 ,0.0001
Indexed LVEDD, mm/m2 34+ 6 30+ 6 32+ 6 30+ 6 ,0.0001
RVEDD, mma 31+ 7 32+ 8 32+ 7 31+ 7 0.190
Indexed RVEDD, mm/m2a 16+ 4 17+ 5 17+ 4 16+ 4 0.279
LVEF, % 29+ 10 39+ 15 36+ 16 39+ 16 ,0.0001
LV mass, g 404+ 123 351+ 103 372+ 119 348+ 121 ,0.0001
LV mass index, g/m2 212+ 62 182+ 55 196+ 60 181+ 64 ,0.0001
LA, mm 48+ 9 49+ 9 48+ 7 46+ 8 ,0.001
Indexed LA, mm/m2 25+ 5 25+ 6 25+ 5 24+ 5 ,0.001
Septal thickness, mm 11+ 3 12+ 3 12+ 3 12+ 3 ,0.0001
LV posterior wall, mm 11+ 2 11+ 3 11+ 2 11+ 2 0.126
Mitral regurgitation, III/IV 141 (27%) 18 (13%) 20 (13%) 145 (15%) ,0.0001
Normal RV motion 393 (74%) 93 (69%) 111 (72%) 764 (81%) ,0.001
Abnormal LV relaxation 157 (36%) 41 (34%) 46 (37%) 337 (40%) 0.351
Pseudonormal LV relaxation 66 (15%) 18 (15%) 14 (11%) 114 (13%) 0.696
Restrictive LV relaxation 101 (23%) 25 (21%) 25 (20%) 166 (20%) 0.587
Haemoglobin, g/L 131+ 20 131+ 21 130+ 18 132+ 21 0.779
eGFR (mL/min/1.73 m2) 67+ 25 68+ 29 66+ 27 70+ 27 0.052
NT-proBNP or BNP highb 292 (70%) 69 (64%) 83 (72%) 438 (60%) 0.003
ACE inhibitor 356 (67%) 93 (69%) 107 (69%) 618 (66%) 0.684
ARB 118 (22%) 27 (20%) 29 (19%) 206 (22%) 0.799
RAAS blockade 462 (87%) 117 (87%) 135 (88%) 805 (85%) 0.792
Beta-blockers 442 (83%) 102 (76%) 115 (75%) 755 (80%) 0.067
Aldosterone antagonists 332 (62%) 71 (53%) 94 (61%) 467 (50%) ,0.0001
Digoxin 132 (25%) 36 (27%) 43 (28%) 191 (20%) 0.042
Loop diuretics 468 (88%) 116 (87%) 141 (92%) 748 (79%) ,0.0001
Antithrombotics 271 (51%) 79 (59%) 71 (46%) 542 (58%) 0.009
Anticoagulants 226 (42%) 62 (46%) 74 (48%) 368 (39%) 0.090
Erythropoietin stimulation 2 (0.37%) 1 (0.74%) 3 (1.94%) 7 (0.74%) 0.257
Continued
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dilated and weighted LV, more advanced mitral valve regurgitation,
largest QRS duration, and most depressed LVEF. Patients with
RBBB had a more frequent history of ischaemic heart disease
and prior myocardial infarction, a greatest proportion of central
obesity, signs of left and right HF, and abnormal RV motion at
echocardiography. Patients with LAFB presented an intermediate
proportion of risk factors and degree of structural and functional
cardiac involvement, and had a lower prevalence of previous myo-
cardial infarction than patients with LBBB or RBBB. However, de-
terioration of the NYHA functional class and presence of signs of
left and right HF remained highly expressed in patients with LAFB.
Patients free of IVCDs were more often women, with less enlarged
left ventricles and less depressed LVEF. The mean haemoglobin
values were normal, but anaemia was present in 673 patiens
(38%). Anaemic patients were distributed similarly among the
study groups, and had lower GFR (61 vs. 73 mL/min/1.73 m2)
and received more antithrombotics (63% vs. 49%) and diuretics
(88% vs. 81%) than non-anaemic patients (P, 0.001).
Erythropoietin-stimulating agents were administered in 13 patients
(0.73%).
The percentage of drug prescription varied among the study cat-
egories. Patients with LBBB tended to receive more beta-blockers,
whereas loop diuretics were used more in patients with RBBB or
LAFB. At the end of the follow-up, the total percentage of patients
with ACE inhibitors changed from 68% at inclusion to 63% (P,
0.001), aldosterone antagonists from 54% to 51% (P ¼ 0.012),
and diuretics from 82% to 78% (P, 0.001), but the percentage
of renin–angiotensin–aldosterone system (RAAS) blockers
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Table 1 Continued
Variables LBBB
(n 5 532, 30.2%)
RBBB
(n5 134, 7.6%)
LAFB
(n 5 154, 8.7%)
No IVCDs
(n5 942, 53.5%)
P-value
ICD 59 (11%) 12 (9%) 13 (8%) 70 (7%) 0.125
CRT/CRT-D 26 (5%) 4 (3%) 9 (6%) 12 (1%) ,0.001
Qualitative data are presented as absolute frequencies and percentages. Quantitative data are expressed as mean+ SD.
AMI, acute myocardial infarction; BMI, body mass index; CRT-D, CRT with cardioverter defibrillation function; eGFR, estimated glomerular filtration rate (MDRD method); ICD,
implantable cardioverter-defibrillator; IVCD, intraventricular conduction defect; LA, left atrium; LAFB, left anterior fascicular block; LVEDD, left ventricular end-diastolic diameter;
RAAS blockade, renin–angiotensin–aldosterone system blockade; RBBB, right bundle branch block; RVEDD, right ventricular end-diastolic diameter.
aValid cases: 1054 (60%).
bValid cases: 1368 (78%).
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Table 2 Readmissions and mortality rates in heart failure patients with and without intraventricular conduction defects
after a median follow-up of 21 months
Variables LBBB
(n5 532, 30.2%)
RBBB
(n5 134, 7.6%)
LAFB
(n5 154, 8.7%)
No IVCDs
(n5 942, 53.5%)
P-value
Readmissionsa
All-cause readmission 219 (41%) 52 (39%) 46 (30%) 282 (30%) ,0.0001
Heart failure 128 (24%) 36 (27%) 37 (24%) 197 (21%) 0.289
Myocardial ischaemia 35 (7%) 12 (9%) 6 (4%) 59 (6%) 0.370
Arrhythmias 102 (19%) 16 (12%) 13 (8%) 63 (7%) ,0.0001
ICD 23 (4%) 4 (3%) 7 (5%) 36 (4%) 0.873
CRT/CRT-D 72 (14%) 5 (4%) 2 (1%) 10 (1%) ,0.0001
Cardiac transplantation 23 (4%) 5 (4%) 7 (5%) 23 (2%) 0.190
Mortality
All-cause mortality 125 (23%) 36 (27%) 31 (20%) 140 (15%) ,0.0001
Cardiovascular death 99 (19%) 27 (20%) 25 (16%) 106 (11%) ,0.001
Cardiac death 94 (18%) 24 (18%) 21 (14%) 91 (10%) ,0.0001
Pump failure 66 (12%) 23 (17%) 18 (12%) 64 (7%) ,0.0001
Sudden 28 (5%) 1 (1%) 3 (2%) 27 (3%) 0.019
Vascular 5 (1%) 3 (2%) 4 (3%) 15 (2%) 0.308
Extravascular 21 (4%) 5 (4%) 6 (4%) 29 (3%) 0.750
Unknown cause 5 (0.9%) 4 (3.0%) 0 (0%) 5 (0.5%) 0.037
aOne or more readmissions for the same cause.
CRT-D, cardiac resynchronization therapy with cardioverter defibrillation function; ICD, implantable cardioverter-defibrillator; IVCD, intraventricular conduction defect; LAFB,
left anterior fascicular block; RBBB, right bundle branch block.
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(88%) and beta-blockers (82%) remained the same. Similar trends
were observed in all four study groups.
An implantable cardioverter-defibrillator (ICD) was inserted in
154 patients before inclusion (Table 1), and 70 devices (Table 2)
were implanted during the follow-up (65 new implants and 5 reim-
plants). The proportion of implanted ICDs among the four groups
did not differ significantly. CRT was applied to 140 patients (51
before inclusion and 89 during the follow-up), and in 117 of them
(83%) an ICD was added to the CRT (CRT-D). Thus, the total
number of patients with ICD either alone or in combination with
CRT was 330 (19% of the study cohort). The percentage of implant-
ation of aCRT/CRT-Dwas 18% in LBBB, 7% inRBBB, 7% in LAFB, and
2% in the no IVCD group (P, 0.001). In 69% of cases, the ICD was
implanted for primary prevention and 18% of patients received ap-
propriate shocks to treat severe ventricular arrhythmias.
Outcomes
Patients were followed for a median of 21 months (interquartile
range 11–33) and 15 of them (0.9%) were lost to follow-up. Non-
emergency heart transplant was performed in 43 patients (2.4%).
There were 666 readmissions due to decompensated HF, 148
due to myocardial ischaemia, and 222 due to arrhythmias. Death
occurred in 332 patients (interannual mortality rate of 10.8%).
Causes of death were: cardiovascular in 257 (77.4%), extravascular
in 61 (18.4%), and of unknown origin in 14 (4.2%) patients. Among
the cardiac deaths, 171 were due to pump failure and 59 occurred
suddenly. As shown in Table 2, patients with RBBB or LBBB had the
highest rates of readmissions and mortality, followed by patients
with LAFB, and finally by patients free of IVCDs. After adjustment
for age, prior myocardial infarction, diabetes, central obesity, mitral
valve regurgitation, signs of left and right HF, LVEF, left atrial size,
LV mass, haemoglobin, renal function, ICD, CRT, and drug
therapy, the Cox model showed that RBBB and LBBB but not
LAFB continued to carry a 21-month mortality risk higher than
that of patients free of IVCDs (Figure 1, Table 3). Although not sig-
nificant, the hazard ratio for readmission, cardiac death, and pump
failure death tended to be higher in the RBBB than in the LBBB
group. In the multivariate analysis, the most prevailing predictors
of these events were diabetes mellitus, prior myocardial infarction,
presence of signs of left and right HF, anaemia, and decreased GFR
(Supplementary material, Table S1). The beneficial effect of ICD
and CRT on cardiac death and pump failure death did not reach
Figure 1 Adjusted Cox model survival curves for readmissions (A), cardiac death (B), and pump failure death (C) in patients with chronic
heart failure with and without intraventricular conduction defects (IVCDs) after a median follow-up of 21 months. LAFB, left anterior fascicular
block; LBBB, left bundle branch block; RBBB, right bundle branch block.
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Table 3 Hazard ratios for readmissions and cardiac
mortality in heart failure patients with and without
intraventricular conduction defects after a median
follow-up of 21 months
P-value HR 95% CI for HR
Lower Upper
All-cause readmissiona
LBBB vs. no IVCD 0.123 1.172 0.958 1.433
RBBB vs. no IVCD 0.018 1.433 1.063 1.930
LAFB vs. no IVCD 0.459 0.887 0.646 1.218
Cardiac deathb
LBBB vs. no IVCD 0.005 1.579 1.149 2.169
RBBB vs. no IVCD 0.007 1.894 1.192 3.008
LAFB vs. no IVCD 0.336 1.266 0.783 2.049
Pump failure deathc
LBBB vs. no IVCD 0.015 1.600 1.097 2.335
RBBB vs. no IVCD 0.0001 2.620 1.603 4.283
LAFB vs. no IVCD 0.139 1.492 0.878 2.535
AMI, acute myocardial infarction; CI, confidence interval; eGFR, estimated
glomerular filtration rate (MDRD method); HR, hazard ratio; ICD, implantable
cardioverter-defibrillator; IVCD, intraventricular conduction defect; LA, left atrial;
LAFB, left anterior fascicular block; RAAS blockade: renin–angiotensin–
aldosterone system blockade; RBBB: right bundle branch block.
aAdjusted for: age, ICD, CRT, signs of left HF, signs of right HF, LVEF, diabetes
mellitus, prior AMI, LV mass index, haemoglobin, eGFR, and loop diuretics.
bAdjusted for: age, ICD, CRT, signs of left HF, signs of right HF, LVEF, diabetes
mellitus, prior AMI, LV mass index, indexed LA diameter, mitral valve regurgitation
III/IV, haemoglobin, beta-blockers, and RAAS blockade.
cAdjusted for: age, ICD, CRT, signs of left HF, signs of right HF, LVEF, diabetes
mellitus, LV mass index, indexed LA diameter, haemoglobin, eGFR, beta-blockers,
and RAAS blockade.
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statistical significance. In contrast, prescription of beta-blockers
and RAAS blockers predicted significant benefit on mortality risk
(Supplementary material, Table S1).
During the follow-up, 65 de novo cases of IVCDs were recorded:
26 LBBB, 20 RBBB, and 19 LAFB. Patients with new onset of IVCDs
continued to be ascribed to the free of IVCDs group because
patient categorization was done according to the inclusion ECG.
Discussion
This study provides integrative information on the clinical and
prognostic influence of the most frequent IVCDs in a cohort of
patients with chronic HF. Differences in the clinical profile and
21-month risk of readmissions and cause of death were observed
among patients with LBBB, RBBB, and LAFB, and in those without
IVCDs.
Clinical characteristics
A clinical phenotype characterized by LV dilation with markedly
depressed systolic function, advanced mitral valve regurgitation,
and history of dilated cardiomyopathy was more often observed in
patients with LBBB. In contrast, patients with RBBB presented with
overt signs of right and left HF, more depressed RV motion at echo-
cardiography, and more frequently reported a history of coronary
heart disease. On the other hand, patients with LAFB showed inter-
mediate degrees of structural LV derangements with respect to
LBBB and RBBB, although they still presented marked signs of left
and right HF and advanced NYHA functional class. Patients free of
IVCDs were more often women with less enlarged left ventricles
and less depressed LVEF, suggesting a predominance of a diastolic
rather than a systolic dysfunctional substrate. The clinical–ECG
associations described in this study have not been previously recog-
nized, due to the lack of studies analysing more than two IVCDs in
the same cohort. On the other hand, not all studies assessing the
prognosis of both LBBB and RBBB in the same series of
patients8,10–12 have provided echocardiographic information, and,
moreover, specific data on relevant structural cardiac features
such as LV mass, LV diameter, or LA size, or resynchronization ther-
apies were not reported in these studies. However, specific findings
such as theobservation of amore advancedmitral valve regurgitation
in patients with LBBB in one study,8 or the higher prevalence of pre-
vious myocardial infarction in HF patients with RBBB reported in
three studies8,11,12 are in agreement with the clinical patterns
found in our patients. Furthermore, there is a coherence between
the pharmacological treatment instituted in our patients and their
clinical phenotype, since, in accordance with the predominance of
LV dilation in patients with LBBB, they receivedmore CRT and beta-
blockers. Likewise, patients with RBBB received more loop diuretics
in consonancewith their advanced signs of congestiveHFand greater
percentage of depressed RVmotion at echocardiography. It is there-
fore unlikely that the clinical associations observed in our study were
fortuitous as they share clinical and pathophysiological plausibility.
The mechanistic foundation for the association between LBBB and
LV dilation is provided by experimental observations demonstrating
that LBBB itself is able to induce LV dilation.5 On the other hand, LV
dilation could secondarily induce LBBB because the increased wall
stress linked to the dilated cavity24 may overstretch the left bundle
branch fibres and then impair conduction through them. An
example of impairment of bundle branch conduction secondary to
ventricular dilation is the occurrence of RBBB in the course of pul-
monary thrombo-embolism.25
Outcomes
The prognosis of LBBB has been assessed in several clinical regis-
tries,7–12,26,27 and although most of them found a worse outcome
in patients with LBBB, other studies reported a more unfavourable
prognosis linked to RBBB. In a cohort of 5517 patients with con-
gestive HF,7 patients with LBBB (n ¼ 1391) showed a higher
1-year all-cause mortality and sudden death than controls free of
LBBB. An unfavourable prognosis of LBBB was also observed in
a cohort of patients with acute HF 1 year after admission.9
However, studies simultaneously comparing the prognosis of
LBBB and RBBB in the same cohort of patients have not afforded
consistent results since some of these studies report a more un-
favourable prognosis in LBBB, whereas others found increased
mortality risk in patients with RBBB. Indeed, in a series of 9082
hospitalized HF patients with LBBB (n ¼ 1480) and RBBB (n ¼
651) followed for 5 years, the adjusted risk of death was higher
in patients with LBBB than in those with RBBB.10 Likewise, in a
cohort of 110 000 subjects free of cardiovascular disease followed
up for 9.5 years, 310 subjects developed BBB (LBBB, 112; RBBB,
198), and those with LBBB presented increased prevalence of
cardiovascular disease and higher cardiac mortality than age- and
sex-matched controls.13 In contrast, a study including 3200 hospi-
talized patients with acute HF showed that rehospitalization and
death occurred more frequently in patients with RBBB (n ¼ 118)
than in those with LBBB (n ¼ 107).12 Likewise, in a cohort of
1888 patients with HF and LVEF ,50%, RBBB (n ¼ 193) had a
4-year all-cause mortality higher than LBBB (n ¼ 306).11 Finally, a
comparable all-cause mortality of LBBB and RBBB was observed
in patients with decompensated HF 23 months after being admit-
ted to an intensive care unit.8
Over the last 10 years, randomized trials have consistently
demonstrated a significant reduction in morbidity and mortality
in patients with mild to advanced HF and prolonged QRS
complex duration treated with CRT,28,29 particularly when an
ICD is added to the CRT.29 In our study, the beneficial effect of
CRT on mortality in the Cox model did not reach statistical signifi-
cance even though 83% of the 140 CRT-implanted patients had an
added ICD and, therefore, an optimal therapy. A rate of CRT im-
plantation higher than ours could theoretically mitigate the worse
prognosis of IVCD, but this cannot be ascertained because the
CRT implantation rate is not reported in the above-reviewed
studies on the prognosis of BBB. Moreover, CRT implantation
rates were largely heterogeneous across the European countries:
in 2006 (our study began in January 2007), . 80 devices per
million inhabitants were implanted in six countries, whereas,
40 devices per million inhabitants were implanted in another
four, including Spain.30
In summary, our study reveals that both LBBB and RBBB are
associated with a higher 21-month incidence of cardiac death
and pump failure death than for patients with LAFB and patients
free of IVCDs. Thus, in addition to the advanced therapies
that are currently applied to patients with LBBB (i.e. LV
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resynchronization), a search for more specific therapies in HF
patients with RBBB is warranted.
Study limitations
Among the initially screened cohort of 2254 patients, there were
492 (21.8%) patients who presented either combined BBB, non-
specific IVC, ventricular pacing rhythm, or left posterior fascicular
block. These patients were not included because the objective of
the study was to analyse the specific influence of the three most
common IVCDs.
This study was conducted in tertiary hospitals and, as compared
with patients currently attending primary care services, they prob-
ably presented with more advanced stages of the disease, as
suggested by. 50% of patients in NYHA class III– IV. Therefore,
our results apply to patients with well-defined underlying struc-
tural derangements and not to patients still in the early stages of
the disease. However, knowledge of the prognostic risk factors
detected in patients with evolved HF could guide implementation
of more appropriate measures to slow the clinical progression of
the disease.
Supplementary material
Supplementary material is available at European Journal of Heart
Failure online.
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